Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the fifteen brokerages that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have issued a buy rating and two have issued a strong buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $110.91.
GPCR has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating on shares of Structure Therapeutics in a report on Thursday, November 12th. Weiss Ratings raised shares of Structure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, November 4th. Citigroup restated a “market outperform” rating on shares of Structure Therapeutics in a report on Friday, August 7th. Wall Street Zen cut shares of Structure Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 3rd. Finally, Citizens Jmp reaffirmed a “market outperform” rating and issued a $110.00 target price on shares of Structure Therapeutics in a research report on Wednesday, September 9th.
View Our Latest Analysis on GPCR
Structure Therapeutics Stock Performance
NASDAQ GPCR opened at $16.14 on Friday. The stock has a market cap of $1.13 billion, a P/E ratio of -12.51 and a beta of -1.12. Structure Therapeutics has a fifty-two week low of $16.06 and a fifty-two week high of $94.90. The stock has a 50 day simple moving average of $25.49 and a two-hundred day simple moving average of $44.30.
Structure Therapeutics (NASDAQ:GPCR – Get Free Report) last posted its earnings results on Monday, November 9th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.15). Sell-side analysts predict that Structure Therapeutics will post -2.14 earnings per share for the current year.
Hedge Funds Weigh In On Structure Therapeutics
A number of institutional investors have recently bought and sold shares of the stock. IFP Advisors Inc purchased a new stake in Structure Therapeutics in the second quarter worth about $46,000. Sterling Capital Management LLC grew its holdings in shares of Structure Therapeutics by 63.6% during the 3rd quarter. Sterling Capital Management LLC now owns 3,345 shares of the company’s stock worth $105,000 after acquiring an additional 1,300 shares during the period. Assetmark Inc. raised its position in shares of Structure Therapeutics by 21.4% in the 1st quarter. Assetmark Inc. now owns 2,544 shares of the company’s stock worth $123,000 after acquiring an additional 449 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Structure Therapeutics in the 3rd quarter worth approximately $132,000. Finally, Parallel Advisors LLC raised its position in shares of Structure Therapeutics by 12.7% in the 3rd quarter. Parallel Advisors LLC now owns 8,286 shares of the company’s stock worth $259,000 after acquiring an additional 934 shares in the last quarter. 91.78% of the stock is owned by institutional investors.
Structure Therapeutics Company Profile
Structure Therapeutics is a clinical-stage biopharmaceutical company developing medicines for metabolic and other chronic diseases. Its research approach uses structural biology and computational methods to identify and design small-molecule drug candidates. The company’s pipeline includes aleniglipron, an oral small-molecule GLP-1 receptor agonist being developed for obesity and related metabolic conditions. Structure Therapeutics is also advancing other drug candidates targeting biological pathways associated with metabolic disease.
See Also
- Five stocks we like better than Structure Therapeutics
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Structure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Structure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
